Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 40Breast Neoplasms 23Gliosarcoma 22Esophageal Neoplasms 21Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 19Pancreatic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Rectal Neoplasms 13Glioma 13Brain Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 12Lung Neoplasms 11Head and Neck Neoplasms 11Melanoma 10Astrocytoma 10Sarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Central Nervous System Neoplasms 8Stomach Neoplasms 7Lymphoma, Follicular 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Adenocarcinoma Of Esophagus 6Oropharyngeal Neoplasms 5Neoplasm Metastasis 5Lymphoma 5Carcinoma 5Burkitt Lymphoma 5

Interventions

Radiation 1Paclitaxel 1Chemoradiotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Resectable Esophageal Cancer × Radiation × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡